Related Experiment Video
Updated: Jun 7, 2025
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
2.4K
Cardiac contractility modulation: from molecular patterns to tailored treatment in heart failure subgroups
Nicola Pierucci1, Andrea D'Amato2, Francesca Fanisio3
1Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University of Rome, Rome, Italy - npierucci@gmail.com.
Minerva Cardiology and Angiology
|November 20, 2024
Summary
Cardiac contractility modulation (CCM) therapy improves heart failure symptoms and reduces hospitalizations without increasing oxygen demand. This innovative treatment offers a new option for specific heart failure patients.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Cardiac contractility modulation (CCM) utilizes non-excitatory signals during the myocyte's absolute refractory period.
- CCM demonstrates an inotropic effect without increasing myocardial oxygen consumption, supported by preclinical and clinical data.
Purpose of the Study:
- To review the pathophysiological evidence for CCM.
- To highlight CCM's role in tailored heart failure treatment for specific patient subgroups.
Main Methods:
- Review of preclinical animal studies and randomized clinical trials on CCM.
- Analysis of CCM's effects on gene expression related to heart failure, calcium cycling, and contractile machinery.
Main Results:
- CCM reverses fetal gene programming in heart failure and regulates key cardiac genes.
- Clinical trials show CCM is safe and effective in reducing heart failure hospitalizations and improving patient outcomes.
- CCM is a viable option for heart failure patients with ejection fraction 25-45% and QRS duration <130 ms, unsuitable for CRT.
Conclusions:
- CCM shows promise as an additional therapy for specific heart failure patient subgroups.
- Further research is needed to optimize CCM in tailored heart failure management.
- Investigating multimodality imaging for lead placement and prognostic stratification in CCM patients is crucial.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:26Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:29Pathophysiology of Cardiac Performance
566
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
566
01:22Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343